123 related articles for article (PubMed ID: 22359194)
21. The effect of argatroban on injured endothelial cells by thrombin.
Ueshima S; Fukao H; Okada K; Matsuo O
Blood Coagul Fibrinolysis; 2000 Oct; 11(7):631-9. PubMed ID: 11085283
[TBL] [Abstract][Full Text] [Related]
22. The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
Raaz U; Kaeberich A; Maegdefessel L; Buerke M; Busshardt M; Schubert S; Russ M; Plehn A; Ebelt H; Werdan K; Schlitt A
Thromb Haemost; 2010 Apr; 103(4):808-14. PubMed ID: 20174756
[TBL] [Abstract][Full Text] [Related]
23. Thrombin inhibition in the acute phase of ischaemic stroke using argatroban.
Kario K; Kodama K; Koide M; Matsuo T
Blood Coagul Fibrinolysis; 1995 Jul; 6(5):423-7. PubMed ID: 8589208
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effect of argatroban on thrombin-induced MAP kinase activation.
Hijikata-Okunomiya A; Nakaya Y; Takahashi A; Inoue N; Taniguchi T; Ishikawa Y
Thromb Haemost; 1998 Sep; 80(3):528-9. PubMed ID: 9759645
[No Abstract] [Full Text] [Related]
25. Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.
Kawai H; Yuki S; Sugimoto J; Tamao Y
J Pharmacol Exp Ther; 1996 Aug; 278(2):780-5. PubMed ID: 8768731
[TBL] [Abstract][Full Text] [Related]
26. Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII.
Nielsen VG; Kirklin JK
Blood Coagul Fibrinolysis; 2008 Dec; 19(8):793-800. PubMed ID: 19002046
[TBL] [Abstract][Full Text] [Related]
27. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Imura Y; Stassen JM; Vreys I; Lesaffre E; Gold HK; Collen D
Thromb Haemost; 1992 Sep; 68(3):336-40. PubMed ID: 1440501
[TBL] [Abstract][Full Text] [Related]
28. Effects of locally administered argatroban on restenosis after balloon angioplasty: experimental and clinical study.
Imanishi T; Arita M; Tomobuchi Y; Hamada M; Hano T; Nishio I
Clin Exp Pharmacol Physiol; 1997 Nov; 24(11):800-6. PubMed ID: 9363360
[TBL] [Abstract][Full Text] [Related]
29. Anti-tissue factor short hairpin RNA inhibits breast cancer growth in vivo.
Bluff JE; Amarzguioui M; Slattery J; Reed MW; Brown NJ; Staton CA
Breast Cancer Res Treat; 2011 Aug; 128(3):691-701. PubMed ID: 20830515
[TBL] [Abstract][Full Text] [Related]
30. Early growth response gene-1 and hypoxia-inducible factor-1α affect tumor metastasis via regulation of tissue factor.
Sun L; Liu Y; Lin S; Shang J; Liu J; Li J; Yuan S; Zhang L
Acta Oncol; 2013 May; 52(4):842-51. PubMed ID: 23409769
[TBL] [Abstract][Full Text] [Related]
31. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.
Incampo F; Carrieri C; Semeraro N; Colucci M
Thromb Res; 2014 Nov; 134(5):1110-6. PubMed ID: 25193406
[TBL] [Abstract][Full Text] [Related]
32. Systemic administration of argatroban inhibits protease-activated receptor-1 expression in perihematomal tissue in rats with intracerebral hemorrhage.
Zhou ZH; Qu F; Zhang CD
Brain Res Bull; 2011 Oct; 86(3-4):235-8. PubMed ID: 21803126
[TBL] [Abstract][Full Text] [Related]
33. Argatroban attenuates leukocyte- and platelet-endothelial cell interactions after transient retinal ischemia.
Miyahara S; Kiryu J; Tsujikawa A; Katsuta H; Nishijima K; Miyamoto K; Yamashiro K; Nonaka A; Honda Y
Stroke; 2003 Aug; 34(8):2043-9. PubMed ID: 12869718
[TBL] [Abstract][Full Text] [Related]
34. Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction.
Siegmund R; Boer K; Poeschel K; Wolf G; Deufel T; Kiehntopf M
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):288-93. PubMed ID: 18469550
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
[TBL] [Abstract][Full Text] [Related]
36. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN
Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795
[TBL] [Abstract][Full Text] [Related]
37. Thrombin inhibitor reduces leukocyte-endothelial cell interactions and vascular leakage after scatter laser photocoagulation.
Musashi K; Kiryu J; Miyamoto K; Miyahara S; Katsuta H; Tamura H; Hirose F; Yoshimura N
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2561-6. PubMed ID: 15980248
[TBL] [Abstract][Full Text] [Related]
38. Development of argatroban, a direct thrombin inhibitor, and its clinical application.
Matsuo T; Koide M; Kario K
Semin Thromb Hemost; 1997; 23(6):517-22. PubMed ID: 9469623
[TBL] [Abstract][Full Text] [Related]
39. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells.
Nakata A; Tsujimura T; Sugihara A; Okamura H; Iwasaki T; Shinkai K; Iwata N; Kakishita E; Akedo H; Terada N
Anticancer Res; 1999; 19(5B):4131-8. PubMed ID: 10628364
[TBL] [Abstract][Full Text] [Related]
40. Coagulation laboratory testing in patients treated with argatroban.
Walenga JM; Fasanella AR; Iqbal O; Hoppensteadt DA; Ahmad S; Wallis DE; Bakhos M
Semin Thromb Hemost; 1999; 25 Suppl 1():61-6. PubMed ID: 10357154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
